UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ~~______________~~____________

Commission file number: 001-33216

SONOMA PHARMACEUTICALS, INC.

(Name of registrant as specified in its charter)

Delaware	68-0423298
(State or other jurisdiction of Incorporation or Organization)	(I.R.S. Employer identification No.)

5445 Conestoga Court, Suite 150, Boulder, CO	80301
(Address of principal executive offices)	(Zip Code)

(800) 759-9305

(Registrant’s telephone number, including area code)

N/A

(Former name or former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, $0.0001 par value	SNOA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated Filer ☐	Accelerated Filer ☐
Non-accelerated Filer ☒	Smaller reporting company ☒
Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock, par value $0.0001 per share, as of ~~August~~November 73, 2025 was 1,~~643~~701,~~265~~076.

SONOMA PHARMACEUTICALS, INC.

Index

		Page
PART I - FINANCIAL INFORMATION
Item 1.	Unaudited Financial Statements	3
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Comprehensive Loss	4
	Condensed Consolidated Statements of Cash Flows	5
	Condensed Consolidated Statements of Changes in Stockholders’ Equity	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1516
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2226
Item 4.	Controls and Procedures	2226
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	2427
Item 1A.	Risk Factors	2427
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2427
Item 3.	Defaults Upon Senior Securities	2427
Item 4.	Mine Safety Disclosures (Not applicable.)	2427
Item 5.	Other Information	2427
Item 6.	Exhibits	2428
	Signatures	2831

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

	June 30, 2025			March 31, 2025
	September 30, 2025			March 31, 2025
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	3,~~605~~035		$	5,374
Accounts receivable, net		2,~~602~~703			2,232
Inventories, net		3,~~802~~634			2,915
Prepaid expenses and other current assets		2,~~868~~925			1,915
Current portion of deferred consideration, net of discount		~~230~~204			212
Total current assets		1312,~~107~~501			12,648
Property and equipment, net		~~301~~284			225
Operating lease, right of use assets		~~536~~479			84
Deferred tax asset, net		~~546~~508			589
Deferred consideration, net of discount, less current portion		24–			73
Other assets		8084			74
Total assets	$	1413,~~594~~856		$	13,693
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	21,~~046~~404		$	953
Accrued expenses and other current liabilities		12,~~836~~024			2,224
Deferred revenue, current portion		~~731~~750			641
Short-term debt		~~139~~56			220
Operating lease liabilities, current portion		9688			58
Total current liabilities		4,~~848~~322			4,096
Deferred revenue, net of current portion		4–			17
Withholding tax payable		5,~~246~~356			5,142
Operating lease liabilities, less current portion		~~440~~391			27
Total liabilities		10,~~538~~069			9,282
Commitments and Contingencies (Note 5)		–
Stockholders’ Equity:
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at June 30, 2025 and March 31, 2025, no shares issued and outstanding at June 30, 2025 and March 31, 2025		–			–
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2025 and March 31, 2025, no shares issued and outstanding at September 30, 2025 and March 31, 2025		–			–
Common stock, $0.0001 par value; 50,000,000 shares authorized at June 30, 2025 and March 31, 2025, 1,642,765 and 1,634,265 shares issued and outstanding at June 30, 2025 and March 31, 2025, respectively (Note 1)		–			–
Common stock, $0.0001 par value; 50,000,000 shares authorized at September 30, 2025 and March 31, 2025, 1,649,765 and 1,634,265 shares issued and outstanding at September 30, 2025 and March 31, 2025, respectively (Note 1)		–			–
Additional paid-in capital		206,~~673~~733			206,593
Accumulated deficit		(199,~~047~~581	)		(197,806	)
Accumulated other comprehensive loss		(3,~~570~~365	)		(4,376	)
Total stockholders’ equity		43,~~056~~787			4,411
Total liabilities and stockholders’ equity	$	1413,~~594~~856		$	13,693

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except per share amounts)

(Unaudited)

	Three Months Ended June 30,
	Three Months Ended September 30,						Six Months Ended September 30,
	2025			2024			2025			2024
Revenues	$	45,~~015~~604		$	3,~~391~~579		$	9,619		$	6,970
Cost of revenues		23,~~551~~484			2,~~085~~218			6,035			4,303
Gross profit		12,~~464~~120			1,~~306~~361			3,584			2,667
Operating expenses:
Research and development		~~594~~575			~~470~~506			1,169			976
Selling, general and administrative		1,~~965~~882			21,~~009~~705			3,847			3,714
Total operating expenses		2,~~559~~457			2,~~479~~211			5,016			4,690
Loss from operations		(~~1,095~~337	)		(~~1,173~~850	)		(1,432	)		(2,023	)
Other (expense) income, net		(~~147~~394	)		~~176~~387			(541	)		563
Loss from operations before income taxes		(1,242	)		(997	)
Net loss before income taxes		(731	)		(463	)		(1,973	)		(1,460	)
Income tax benefit (expense)		1197			(~~146~~147	)		198			(293	)
Net loss	$	(~~1,241~~534	)	$	(~~1,143~~610	)	$	(1,775	)	$	(1,753	)
Net loss per share: basic and diluted	$	(0.7632	)	$	(10.3459	)	$	(1.08	)	$	(1.86	)
Weighted-average shares outstanding: basic and diluted		1,641			851
Weighted-average number of shares outstanding: basic and diluted		1,646			1,034			1,643			943
Other comprehensive loss:
Net loss	$	(~~1,241~~534	)	$	(~~1,143~~610	)	$	(1,775	)	$	(1,753	)
Foreign currency translation adjustments		~~806~~205			(~~881~~593	)		1,011			(1,474	)
Comprehensive loss	$	(~~435~~329	)	$	(21,~~024~~203	)	$	(764	)	$	(3,227	)

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Three Months Ended June 30,
	Six Months Ended September 30,
	2025			2024
Cash flows from operating activities:
Net loss	$	(1,~~241~~775	)	$	(1,~~143~~753	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		3672			3974
Stock-based compensation		5796			~~107~~121
Deferred income tax expense		93			122
Deferred tax asset		141			188
Operating lease right-of-use asset		(~~448~~392	)		55102
Changes in operating assets and liabilities:
Accounts receivable, net		(~~216~~294	)		(~~470~~427	)
Inventories, net		(~~652~~444	)		(~~114~~370	)
Prepaid expenses and other current assets		(~~819~~834	)		591,134
Deferred consideration, net of discount		55114			5399
Accounts payable		~~1,026~~360			~~182~~219
Accrued expenses and other current liabilities		(~~484~~326	)		~~186~~62
Withholding tax payable		~~104~~214			~~112~~223
Operating lease liabilities		~~448~~392			(55102	)
Deferred revenue		26			(45128	)
Net cash used in operating activities		(2,~~015~~650	)		(~~912~~558	)
Cash flows from investing activities:
Purchases of property and equipment		(~~106~~116	)		(531	)
Net cash used in investing activities		(~~106~~116	)		(531	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering expenses		–			~~748~~2,289
Proceeds from exercise of employee stock options		2344			733
Principal payments on short-term debt		(81	)		(119	)
Payments for fractional shares related to reverse-split		–			(1	)
Net cash (used in) provided by financing activities		(58	)		636
Principal payments on short-term debt		(164	)		(241	)
Effect of exchange rate on cash and cash equivalents		410			(258	)
Net cash (used in) provided by financing activities		(120	)		2,080
Net decrease in cash and cash equivalents		(1,769	)		(539	)
Effect of exchange rate on cash and cash equivalents		547			(541	)
Net (decrease) increase in cash and cash equivalents		(2,339	)		950
Cash and cash equivalents, beginning of period		5,374			3,128
Cash and cash equivalents, end of period	$	3,~~605~~035		$	24,~~589~~078
Supplemental disclosure of cash flow information:
Cash paid for interest	$	35		$	58
Cash paid for taxes	$	623		$	–

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE ~~THREE~~SIX MONTHS ENDED ~~JUNE~~SEPTEMBER 30, 2025 AND 2024

(In thousands, except share amounts)

(Unaudited)

	Common Stock ($0.0001 par Value)				Additional Paid in		Accumulated			Accumulated Other Comprehensive
	Shares		Amount		Capital		Deficit			Loss			Total
Balance, March 31, 2025		1,634,265	$	–	$	206,593	$	(197,806	)	$	(4,376	)	$	4,411
Exercise of employee stock options		8,500		–		23		–			–			23
Employee stock-based compensation		–		–		57		–			–			57
Foreign currency translation adjustment		–		–		–		–			806			806
Net loss		–		–		–		(1,241	)		–			(1,241	)
Balance, June 30, 2025		1,642,765	$	–	$	206,673	$	(199,047	)	$	(3,570	)	$	4,056
Exercise of employee stock options		7,000		–		21		–			–			21
Employee stock-based compensation		–		–		39		–			–			39
Foreign currency translation adjustment		–		–		–		–			205			205
Net loss		–		–		–		(534	)		–			(534	)
Balance, September 30, 2025		1,649,765	$	–	$	206,733	$	(199,581	)	$	(3,365	)	$	3,787

	Common Stock ($0.0001 par Value)					Additional Paid in			Accumulated			Accumulated Other Comprehensive
	Shares			Amount		Capital			Deficit			Loss			Total
Balance, March 31, 2024		780,371		$	–	$	203,209		$	(194,349	)	$	(2,723	)	$	6,137
Proceeds from At-the-Market sale of common stock, net of offering expenses		158,311			–		748			–			–			748
Exercise of employee stock options		2,000			–		7			–			–			7
Employee stock-based compensation		9,538			–		107			–			–			107
Foreign currency translation adjustment		–			–		–			–			(881	)		(881	)
Net loss		–			–		–			(1,143	)		–			(1,143	)
Balance, June 30, 2024		950,220		$	–	$	204,071		$	(195,492	)	$	(3,604	)	$	4,975
Proceeds from At-the-Market sale of common stock, net of offering expenses		381,433			–		1,541			–			–			1,541
Exercise of employee stock options		7,250			–		26			–			–			26
Payments for fractional shares related to reverse-split		(288	)		–		(1	)		–			–			(1	)
Employee stock-based compensation		–			–		14			–			–			14
Foreign currency translation adjustment		–			–		–			–			(593	)		(593	)
Net loss		–			–		–			(610	)		–			(610	)
Balance, September 30, 2024		1,338,615		$	–	$	205,651		$	(196,102	)	$	(4,197	)	$	5,352

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Rounded to nearest thousand unless specified)

(Unaudited)

Note 1.

Organization and Recent Developments

Organization

Sonoma Pharmaceuticals, Inc. (the “Company”) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware in December 2006. The Company moved its principal office from Petaluma, California to Woodstock, Georgia in June 2020 and to Boulder, Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care, and as a non-toxic disinfectant. The Company’s products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The Company sells its products either directly or via partners in 55 countries worldwide.

Reverse Stock Split

Effective August 29, 2024, the Company effected a a reverse stock split of its common stock, par value $0.0001 per share. Every twenty shares of common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each fractional share was settled with cash. The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 21,174,693 to 1,058,447. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001. ~~The reverse stock split has been retroactively applied to all share and per share amounts in the condensed consolidated financial statements and accompanying footnotes.~~

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended March 31, 2025, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on June 17, 2025.

Note 2.

Liquidity and Financial Condition

The Company reported a net loss of $1534,~~241~~000 and $610,000 for the three months ended September 30, 2025 and 2024, respectively, and $1,~~143~~775,000 and $1,753,000 for the ~~three~~six months ended ~~June~~ September 30, 2025 and 2024, respectively. At ~~June~~September 30, 2025 and March 31, 2025, the Company’s accumulated deficit amounted to $199,~~047~~581,000 and $197,806,000, respectively. The Company had working capital of $8,~~259~~179,000 and $8,552,000 as of ~~June~~September 30, 2025 and March 31, 2025, respectively. The cash balance at September 30, 2025 and March 31, 2025 was $3,035,000 and $5,374,000, respectively. During the ~~three~~six months ended ~~June~~September 30, 2025 and 2024, net cash used in operating activities amounted to $2,~~015~~650,000 and $~~912~~558,000, respectively.

Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the economic climate in the U.S. deteriorates, the Company’s ability to raise additional capital could be negatively impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. This uncertainty along with the Company’s history of losses indicates that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the economic climate in the U.S. deteriorates, the Company’s ability to raise additional capital could be negatively impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. This uncertainty along with the Company’s history of losses indicates that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

Note 3.

Summary of Significant Accounting Policies

Use of Estimates

The preparation of condensed consolidated financial ~~statements~~ statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and ~~liabilities~~ liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance relating to the Company’s deferred tax assets. Periodically, the Company evaluates and adjusts estimates accordingly.

Net Loss per Share

The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

Schedule of computation of basic and diluted net loss per share
	For the Three Months Ended June 30,
	Three Months Ended September 30,						Six Months Ended September 30,
(In thousands, except per share data)	2025			2024
	2025			2024			2025			2024
Net loss	$	(1,241	)	$	(1,143	)
Numerator:
Weighted-average number of common shares outstanding: basic and diluted		1,641			851
Net loss	$	(534,000	)	$	(610,000	)	$	(1,775,000	)	$	(1,753,000	)
Net loss per share: basic and diluted	$	(0.76	)	$	(1.34	)
Denominator:
Weighted-average number of common shares outstanding: basic and diluted		1,646,000			1,034,000			1,643,000			943,000
Net loss per share: basic and diluted	$	(0.32	)	$	(0.59	)	$	(1.08	)	$	(1.86	)

The computation of basic and diluted loss per share for the three months ended June 30, 2025 and 2024 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.8

Schedule of antidilutive shares
	June 30,
(In thousands)	2025		2024
Common stock to be issued upon vesting of restricted stock units		106		–
Common stock to be issued upon exercise of options		72		50
		178		50

The computation of basic and diluted loss per share for the three and six months ended September 30, 2025 and 2024 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.

Schedule of antidilutive shares
	Three Months Ended September 30,				Six Months Ended September 30,
	2025		2024		2025		2024
Common stock to be issued upon vesting of restricted stock units		106,000		–		106,000		–
Common stock to be issued upon exercise of options		66,000		42,000		66,000		42,000
		172,000		42,000		172,000		42,000

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.

The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology and products.

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled.

The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance.

Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.

The Company assessed the promised goods and services in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation. At ~~June~~September 30, 2025, March 31, 2025 and March 31, 2024, the Company had deferred revenue related to Invekra in the amounts of $6147,000, $69,000 and $152,000, respectively.

Accounts Receivable

Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends.

The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company did not deem it necessary to record an allowance for doubtful accounts for probable credit losses at ~~June~~September 30, 2025, March 31, 2025 and March 31, 2024. At ~~June~~September 30, 2025, March 31, 2025 and March 31, 2024, the Company’s accounts receivable, net balances are $2,~~602~~703,000, $2,232,000 and $2,898,000, respectively. Additionally, at ~~June~~September 30, 2025, March 31, 2025 and March 31, 2024, the Company has allowances of $19,000, $8,000 and $27,000, respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in accounts receivable, net in the accompanying condensed consolidated balance sheets.

Inventories

Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.

Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At June 30, 2025 and March 31, 2025, the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $304,000 and $298,000, respectively, which is included in inventories, net in the accompanying condensed consolidated balance sheets.

Segment Reporting

The Company has one primary business activity and operates in one reportable segment. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer (“CEO”) who evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. The measures of profitability and the significant segment expenses reviewed by the CODM are consistent with these financial statements and footnotes.

Recent Accounting Standards

Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, establishes incremental disaggregation of income tax disclosure pertaining to the effective tax rate reconciliation and income taxes paid. This standard is effective for fiscal years beginning after December 31, 2024 and requires prospective application with the option to apply it retrospectively. The Company intends to adopt this standard in its Annual Report on Form 10-K for the year ended March 31, 2026. The Company is currently evaluating the potential impact of adopting the standard on its disclosures.

This and other accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.

Note 4.

Condensed Consolidated Balance Sheet

Inventories, net

Inventories, net consist of the following:

Schedule of inventories, net
	June 30,			March 31,
	September 30,			March 31,
	2025			2025
Raw materials	$	1,~~755~~974,000		$	1,395,000
Finished goods		21,~~351~~965,000			1,818,000
Inventories, gross		43,~~106~~939,000			3,213,000
Less: allowance for obsolete and excess inventory		(~~304~~305,000	)		(298,000	)
Total inventories, net	$	3,~~802~~634,000		$	2,915,000

Leases

The Company’s operating leases are comprised primarily of facility leases. Balance sheet information related to the Company’s leases is presented below:

Schedule of lease information
	June 30,		March 31,
	September 30,		March 31,
	2025		2025
Operating leases:
Operating lease right-of-use assets	$	~~536~~479,000	$	84,000
Operating lease liabilities – current		9688,000		58,000
Operating lease liabilities – non-current		~~440~~391,000		27,000

Other information related to leases is presented below:

Three Months Ended September 30, 2025
Operating lease cost	$	187,000
Other information:
Operating cash flows from operating leases	$	(392,000	)
Weighted-average remaining lease term – operating leases (in months)		51.6
Weighted-average discount rate – operating leases		10.8%

Three Months Ended June 30, 2025
Operating lease cost	$	87,000
Other information:
Operating cash flows from operating leases	$	(448,000	)
Weighted-average remaining lease term – operating leases (in months)		53.3
Weighted-average discount rate – operating leases		10.7%

As of September 30, 2025, the annual minimum lease payments of our operating lease liabilities were as follows:

As of June 30, 2025, the annual minimum lease payments of our operating lease liabilities were as follows:


For Years Ending March 31,
2026 (excluding the three months ended September 30, 2025)	$	77,000
2027		131,000
2028		133,000
2029		130,000
2030		137,000
Thereafter		12,000
Total future minimum lease payments, undiscounted		620,000
Less: imputed interest		(141,000	)
Present value of future minimum lease payments	$	479,000

Schedule of minimum lease payments of operating lease liabilities
For Years Ending March 31,
2026 (excluding the three months ended June 30, 2025)	$	126,000
2027		139,000
2028		146,000
2029		149,000
2030		164,000
Thereafter		13,000
Total future minimum lease payments, undiscounted		737,000
Less: imputed interest		(201,000	)
Present value of future minimum lease payments	$	536,000

Note 5.

Commitments and Contingencies

Legal Matters

The Company may be involved in legal matters arising in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss.

Employment Matters

~~The~~At September 30, 2025, the Company ~~has~~had employment agreements in place with two of its key executives. These executive employment agreements ~~provide~~provided, among other things, for the payment of up to eighteen months of severance compensation for terminations under certain circumstances.

As of ~~June~~September 30, 2025, with respect to these agreements, aggregated annual salaries was $675,000 and potential severance payments to these key executives is $1,519,000 if triggered.

Note 6.

Debt

Financing of Insurance Premiums

On February 1, 2025, the Company entered into a note agreement for $274,000 with an interest rate of 7.97% per annum with final payment on November 1, 2025. This instrument was issued in in connection with financing insurance premiums. At ~~June~~September 30, 2025 and March 31, 2025, the outstanding principal on the note amounted to to $~~139~~56,000 and $220,000, respectively.

Note 7.

Stock-Based Compensation

For the three months ended ~~June~~September 30, 2025 and 2024, the Company incurred $39,000 and $14,000 of stock-based compensation expense, respectively. For the six months ended September 30, 2025 and 2024, the Company incurred $5796,000 and $~~107~~121,000 of stock-based compensation expense, respectively. All stock-based compensation incurred is included in selling, general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss.

For the ~~three~~six months ended ~~June~~September 30, 2025, the Company estimated the fair value of employee and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options was estimated using the following weighted-average assumptions:


	Weighted -
	Average
	Assumptions
Fair value of the Company’s common stock on date of grant	$	2.85
Expected term		5 years
Risk-free interest rate		4.38%
Dividend yield		0%
Volatility		112.56%
Fair value of options granted	$	2.32

At ~~June~~September 30, 2025, there was unrecognized compensation costs of $~~233~~151,000 related to stock options which is expected to be recognized over a weighted-average amortization period of 1.3313 years.

Stock options award activity is as follows:

Schedule of stock options award activity
	Number of Shares			Weighted- Average Exercise Price
Outstanding at April 1, 2025		73,081		$	43.27
Options granted		9,000			2.85
Options exercised		(815,500	)		2.6881
Options forfeited		(~~1,074~~229	)		791,006.1545
Options expired		–			–
Outstanding at September 30, 2025		66,352		$	43.70
Outstanding at June 30, 2025		72,507		$	42.47
Exercisable at September 30, 2025		35,353		$	78.17
Exercisable at June 30, 2025		39,177		$	73.86

The aggregate intrinsic value of stock options is is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock, or $23.8588 per share at ~~June~~September 30, 2025.

Restricted stock award activity is as follows:

Schedule of restricted stock award activity
	Number of Shares		Weighted Average Award Date Fair Value per Share
Unvested restricted stock awards outstanding at April 1, 2025		45,000	$	2.68
Restricted stock awards granted		60,500		2.85
Restricted stock awards vested		–		–
Unvested restricted stock awards outstanding at September 30, 2025		105,500	$	2.78
Unvested restricted stock awards outstanding at June 30, 2025		105,500	$	2.78

A tax benefit of $2343,000 has been recognized as a a result of non-qualified stock options exercised during the ~~three~~six months ended ~~June~~September 30, 2025.

The Company issues new shares of common stock upon exercise of stock options or release of restricted stock awards.

Note 8.

Income Taxes

At the end of each interim reporting period, the Company determines the income tax provision by using an estimate of the annual effective tax rate, adjusted for discrete items occurring in the quarter.

Our effective tax rate for the three ~~months~~and ~~ended~~six months ~~June~~ended September 30, 2025 was (026.0697)% and (10.03)%. The Company’s effective tax rate for the three months ~~ended~~and ~~June~~six months ended September 30, 2025 differed from the federal statutory tax rate of 21% primarily due to the valuation allowance recognized against deferred tax assets in the U.S and permanent tax adjustment of intercompany interest expense in Mexico and Netherlands.

Judgment is required in determining whether deferred tax assets will be realized in full or in part. Management assesses the available positive and negative evidence on a jurisdictional basis to estimate if deferred tax assets will be recognized and when it is more likely than not that all or some deferred tax assets will not be realized, and a valuation allowance must be established. As of ~~June~~September 30, 2025, the Company continues to maintain a valuation allowance in the U.S.

Note 9.

Revenue Disaggregation

The Company generates product revenues from products which are sold into the human and animal healthcare markets.

The following table presents the Company’s disaggregated revenues by source:

Schedule of disaggregated revenues by revenue source
	Three Months Ended June 30,
	Three Months Ended September 30,				Six Months Ended September 30,
Product	2025		2024
	2025		2024		2025		2024
Human Care	$	35,~~555~~116,000	$	23,~~992~~177,000	$	8,671,000	$	6,169,000
Animal Care		~~460~~488,000		~~399~~402,000		948,000		801,000
Total Product		4,015,000		3,391,000
	$	5,604,000	$	3,579,000	$	9,619,000	$	6,970,000

The following table shows the Company’s revenues by geographic region:

Schedule of revenues by geographic region
	Three Months Ended June 30,
	Three Months Ended September 30,				Six Months Ended September 30,
	2025		2024		2025		2024
United States	$	1,~~005~~449,000	$	~~642~~675,000	$	2,454,000	$	1,317,000
Europe		12,~~468~~151,000		1,~~288~~506,000		3,619,000		2,794,000
Asia		~~662~~1,057,000		~~477~~776,000		1,719,000		1,253,000
Latin America		~~564~~532,000		~~880~~465,000		1,096,000		1,345,000
Rest of the World		~~316~~415,000		~~104~~157,000		731,000		261,000
Total	$	45,~~015~~604,000	$	3,~~391~~579,000	$	9,619,000	$	6,970,000

Note 10.

Significant Customer Concentrations

The following table shows major customers revenues as a percentage of net revenue:

Schedule of customer concentrations of risk
	For the Three Months Ended June 30,
	Three Months Ended September 30,				Six Months Ended September 30,
	2025		2024		2025		2024
Customer A		10%		–*%
Customer B		–*%		13%		11%		19%
Customer B		14%		26%
Customer C		17%		19%		18%		19%
Customer C		19%		18%
Customer D		–*%		12%		–*%		–*%

The following table shows major customers accounts receivable balances as a percentage of net accounts receivables:

	June 30,
	September 30,
	2025		2024
Customer A		–*%		16%
Customer B		–*%		17%
Customer C		15%		11%
Customer C		14%		11%
Customer D		10%		20%
Customer D		13%		17%

*	% Represents less than 10%

Note 11. Subsequent Events

Management has evaluated subsequent events or transactions occurring through the date the condensed consolidated financial statements were issued. The Company does not have subsequent events to report.

Note 11.

Subsequent Events

At-the-Market Sale of Common Stock

During October 2025, the Company sold 51,436 shares of common stock for gross proceeds of $232,000 and net proceeds of $170,000 after deducting offering expenses.

Employment Matters

On October 3, 2025, the Company amended and restated the employment agreement with its Chief Executive Officer. The amended and restated employment agreement provides, among other things, for the payment of up to twenty-four months of severance compensation for termination under certain circumstances. Following such events, the annual salary for the Company’s Chief Executive Officer is $475,000 and potential severance payments to the Company’s Chief Executive Officer is $1,425,000 if triggered (Note 5). On October 18, 2025, the Company terminated the employment agreement with its Executive Vice President and Chief Operating Officer.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q as of June 30, 2025 and our audited consolidated financial statements for the year ended March 31, 2025 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on June 17, 2025.

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this report, the words “anticipate,” “suggest,” “estimate,” “plan,” “aim,” “seek,” “project,” “continue,” “ongoing,” “potential,” “expect,” “predict,” “believe,” “intend,” “may,” “will,” “should,” “could,” “would,” “likely,” “proposal,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to the risks described in our Annual Report on Form 10-K and this Quarterly Report on Form 10-Q including: our ability to become profitable; our dependence on third-party distributors; certain tax impacts of inter-company loans between us and our Mexican subsidiary; the progress and timing of our development programs and regulatory approvals for our products; the benefits and effectiveness of our products; the ability of our products to meet existing or future regulatory standards; the progress and timing of clinical trials and physician studies; our expectations and capabilities relating to the sales and marketing of our current products and our product candidates; our ability to compete with other companies that are developing or selling products that are competitive with our products; the establishment of strategic partnerships for the development or sale of products; the risk our research and development efforts do not lead to new products; the timing of commercializing our products; our ability to penetrate markets through our sales force, distribution network, and strategic business partners to gain a foothold in the market and generate attractive margins; the ability to attain specified revenue goals within a specified time frame, if at all, or to reduce costs; the outcome of discussions with the U.S. Food and Drug Administration, or FDA, and other regulatory agencies; the content and timing of submissions to, and decisions made by, the FDA and other regulatory agencies, including demonstrating to the satisfaction of the FDA the safety and efficacy of our products; our ability to successfully transition our European products to the new Medical Device Regulation, or to comply with its ongoing requirements; our ability to manufacture sufficient amounts of our products for commercialization activities; our ability to protect our intellectual property and operate our business without infringing on the intellectual property of others; our ability to continue to expand our intellectual property portfolio; the risk we may need to indemnify our distributors or other third parties; risks attendant with conducting a significant portion of our business outside the United States; fluctuations in foreign currency exchange rates; risks relative to global economic conditions, prospective tariffs or changes to trade policies; our ability to comply with complex federal and state fraud and abuse laws, including state and federal anti-kickback laws; risks associated with changes to health care laws; our ability to attract and retain qualified directors, officers and employees; our expectations relating to the concentration of our revenue from international sales; our ability to expand to and commercialize products in markets outside the wound care market; our ability to protect our information technology and infrastructure; and the impact of any future changes in accounting regulations or practices in general with respect to public companies. These forward-looking statements speak only as of the date hereof. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Our Business

We are a global healthcare leader for developing ~~and~~ and producing stabilized hypochlorous acid, or HOCl, products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Our products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. We sell our products either directly or via partners in over 55 countries worldwide.

1516

Business Channels

Our core market differentiation is based on being the leading developer and producer of stabilized hypochlorous acid, or HOCl, solutions. We have been in business for over 20 years, and in that time, we have developed significant scientific knowledge of how best to develop and manufacture HOCl products backed by decades of studies and data collection along with manufacturing experience.

We sell our products into many markets both in the U.S. and internationally. In international markets, we sell a variety of products into over 55 countries. Our core strategy is to work with partners both in the United States and around the world to market and distribute our products. In some cases, we market and sell our own products.

Dermatology

We have developed unique, differentiated, and safe dermatologic products that support paths to healing for various dermatologic conditions. Our products are primarily targeted at the treatment of redness and irritation, the management of scars and symptoms of eczema/atopic dermatitis. In Europe and the United Kingdom, we have developed products to treat acne. We are strategically focused on introducing innovative new products that are supported by human clinical data with applications that address specific dermatological procedures currently in demand. In addition, we look for markets where we can provide effective product line extensions and pricing to new product families.

In the United States, we relaunched the direct sale of our prescription and office dispense dermatology products in December 2024, including Epicyn Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. We also relaunched over-the-counter Lasercyn Dermal Spray and Lasercyn Gel.

Other over-the-counter dermatology products in ~~the~~ the United States include Regenacyn® Advanced Scar Gel, which is clinically proven to improve the overall appearance of ~~scars~~ scars while reducing pain, itch and redness, Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel for the alleviation of of red bumps, rashes, shallow skin fissures, peeling, and symptoms of eczema/atopic dermatitis, and Rejuvacyn® Advanced ~~Skin~~ Skin Repair Cooling Mist for management of minor skin irritations following cosmetic procedures as well as daily skin health and hydration. Rejuvacyn is certified as a Natural Personal Care Product by the Natural Products Association, and Reliefacyn received the National Eczema Association Seal of AcceptanceTM in 2023 and the National Psoriasis Foundation Seal of Recognition in 2025. In January 2024, we launched LumacynTM Clarifying Mist, a direct-to-consumer skin care product in the United States. Lumacyn is an all-natural daily toner to soothe skin, reduce redness and irritation, and manage blemishes by reducing infection.

Our consumer products are available through online retailers, our online store and third-party distributors. On January 29, 2025, we entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation for the sale of our Microcyn^® technology-based products to large retailers in the United States. The agreement is for an initial term of two years, subject to three automatic one-year renewal periods. We amended the agreement on March 21, June 2, and July 23, 2025 to include additional products for distribution.

In January 2023, we launched a line of office dispense products exclusively for skin care professionals, including two new prescription strength dermatology products, Reliefacyn Plus Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn Plus Skin Repair Cooling Mist. These products, along with Regenacyn Plus Scar Gel, are marketed and sold directly to dermatology practices and medical spas.

We sell dermatology products in international markets through distributors. In these markets, we have a network of partners, ranging from country specific distributors to large pharmaceutical companies to full-service sales and marketing companies. We work with our international partners to create products they can market in their home country. Some products we develop and manufacture are custom label while others use branding we have already developed. We have created or co-developed a wide range of products for international markets using our core HOCl technology.

1617

First Aid and Wound Care

Our HOCl-based wound care products are intended for the treatment of acute and chronic wounds as well as first- and second-degree burns, and as an intraoperative irrigation treatment. They work by first removing foreign material and debris from the skin surface and moistening the skin, thereby improving wound healing. Secondly, our HOCl products assist in the wound healing process by removing microorganisms. HOCl is an important constituent of our innate immune system, formed and released by the macrophages during phagocytosis. Highly organized cell structures such as human tissue can tolerate the action of our wound care solution while single-celled microorganisms cannot, making our products advantageous to other wound-irrigation and antiseptic solutions. Due to its unique chemistry, our wound treatment solution is also much more stable than similar products on the market and therefore maintains much higher levels of hypochlorous acid over its shelf life.

In the United States, we sell our wound care products directly to hospitals, physicians, nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements. In Europe, the Middle East and Asia, we sell our wound care products through a diverse network of distributors.

In June 2023, we announced a new application of our HOCl technology for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. It is in trial use by hospitals in Europe and launched in the U.S. in November 2023.

In April 2024, we announced expansion of our Microcyn Negative Pressure Wound Therapy Solution products line, now available in 250mL, 450mL and 990mL sizes to meet the diverse needs of healthcare professionals and patients.

In August 2024, we entered into a distribution agreement with Medline Industries, LP, for the marketing and distribution of our wound care products in the United States. The agreement is for an initial term of five years, subject to automatic one-year renewal periods. In October 2024, we entered into an amendment to the agreement which allows Medline to also sell our wound care products in Canada, as well as to sell additional over-the-counter wound care products to retailers in both countries.

Eye Care

In the United States, our prescription product Acuicyn^® Eyelid & Eyelash Cleanser is an effective solution for symptoms of blepharitis and the daily hygiene of eyelids and lashes, and helps manage red, itchy, crusty and inflamed eyes. It is strong enough to kill the bacteria that causes discomfort, fast enough to provide near instant relief, and gentle enough to use as often as needed.

We sell Ocucyn^® Eyelid & Eyelash Cleanser to consumers through our online store, and third party distributors. Ocucyn is designed for everyday use as a safe, gentle, and effective solution for good eyelid and eyelash hygiene. In international markets we rely on distribution partners to sell our eye products.

Podiatry

Our HOCl-based wound care products are also indicated for the treatment of diabetic foot ulcers. In the United States, we sell our wound care products directly to podiatrists as well as hospitals, nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements. In Europe, we sell our wound care products for podiatric use through a diverse network of distributors.

In April 2023, we launched ~~PodiacynTM~~Podiacyn® Advanced Everyday Foot Care direct to consumers for over-the-counter use in the United States, intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. Podiacyn is available through ~~Amazon.com,~~ our online store and third-party distributors.

1718

Animal Health Care

MicrocynAH^® is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections. It is intended for the safe and rapid treatment of a variety of animal afflictions including cuts, burns, lacerations, rashes, hot spots, rain rot, post-surgical sites, pink eye symptoms and wounds to the outer ear.

For our animal health products sold in the U.S., we partner with Compana Pet Brands. Compana distributes non-prescription products to national pet-store retail chains and farm animal specialty stores, such as PetSmart, Tractor Supply, and Menards.

For the Asian and European markets, in May 2019 we partnered with Petagon, an international importer and distributor of quality pet food and products, for an initial term of five years. We supply Petagon with all MicrocynAH products sold by Petagon.

Surface Disinfectants

Our HOCl technology has been formulated as a disinfectant and sanitizer solution and is sold in numerous countries. It is designed to be used to spray in aerosol format in areas and environments likely to serve as a breeding ground for the spread of infectious disease, which could result in epidemics or pandemics. The medical-grade surface disinfectant solution is used in hospitals worldwide to protect doctors and patients. In May 2020, Nanocyn® Disinfectant & Sanitizer received approval to be entered into the Australian Register of Therapeutic Goods, or ARTG, for use against the coronavirus SARS-CoV-2, or COVID-19, and was also authorized in Canada for use against COVID-19. Nanocyn has also met the stringent environmental health and social/ethical criteria of Good Environmental Choice Australia, or GECA, becoming one of the very few eco-certified, all-natural disinfectant solutions in Australia. In 2024, the Australian Therapeutic Goods Administration approved extended claims for Nanocyn for use against Candida auris (C. auris) and Clostritium Difficile (C. diff.).

Through our partner MicroSafe, we sell hard surface disinfectant products into Europe, the Middle East and Australia.

In July 2021, we granted MicroSafe the non-exclusive right to sell and distribute Nanocyn in the United States provided that MicroSafe secure U.S. EPA approval. In April of 2022, MicroSafe secured the EPA approval for Nanocyn® Disinfectant & Sanitizer, meaning that it can now be sold in the United States as a surface disinfectant, and it was subsequently added to the EPA’s list N for use against COVID-19. In June 2022, the EPA added Nanocyn to List Q as a disinfectant for Emerging Viral Pathogens, including Ebola virus, Mpox, and SARS-CoV-2, and in March 2023 the EPA added Nanocyn to Lists G and H, for use against Methicillin Resistant Staphylococcus Aureus (MRSA), Salmonella, Norovirus, Poliovirus, and as a fungicide. Nanocyn also received the Green Seal® Certification after surpassing a series of rigorous standards that measure environmental health, sustainability and product performance. Nanocyn is currently sold by MicroSafe in Europe, the Middle East and Australia.

Additional Information

Investors and others should note that we announce material financial information using our company website (www.sonomapharma.com), our investor relations website (ir.sonomapharma.com), SEC filings, press releases, public conference calls and webcasts. The information on, or accessible through, our websites is not incorporated by reference in this Quarterly Report on Form 10-Q.

Results of Operations

Comparison of the Three Months Ended ~~June~~ September 30, 2025 and 2024

Revenue

The following table shows our consolidated total ~~revenue~~ revenue and revenue by geographic region for the three months ended ~~June~~September 30, 2025 and 2024:

Three Months Ended June 30,

Three Months Ended September 30,

(In thousands)

2025

2024

$ Change

% Change

United States

1,~~005~~449

~~642~~675

~~363~~774

57115%

Europe

12,~~468~~151

1,~~288~~506

~~180~~645

1443%

Asia

~~662~~1,057

~~477~~776

~~185~~281

3936%

Latin America

~~564~~532

~~880~~465

~~(316~~67

)

~~(36~~14%

)

Rest of the World

~~316~~415

~~104~~157

~~212~~258

~~204~~164%

Total

45,~~015~~604

3,~~391~~579

~~624~~2,025

1857%

The increase in United States revenue of $~~363~~774,000 for the three months ended ~~June~~September 30, 2025 was primarily the result of an increase in revenue related to human health care products and over-the-counter animal health care products.

The increase in Europe revenue for the three months ended June 30, 2025 of $180,000 was the result of a general increase in demand for our products.

The increase in Asia revenue of $185,000 for the three months ended June 30, 2025 was primarily due to timing of orders. Revenues from our international distributors tend to fluctuate from period to period due to customer placement of larger but less frequent orders to benefit from quantity discounts and reduced shipping costs.

The decrease in Latin America revenue for the three months ended June 30, 2025 of $316,000 was primarily due to timing of customer orders for overflow manufacturing.

The increase in Rest of World revenue for the three months ended June 30, 2025 of $212,000 was primarily due to timing of customer orders.

Cost of Revenue and Gross Profit

The cost of revenue and gross profit metrics for the three months ended June 30, 2025 and 2024 are as follows:

	Three Months Ended June 30,
(In thousands, except for percentages)	2025		2024		$ Change		% Change
Cost of Revenues	$	2,551	$	2,085	$	466		22%
Cost of Revenue as a % of Revenues		64%		61%
Gross Profit	$	1,464	$	1,306	$	158		12%
Gross Profit as a % of Revenues		36%		39%

The increase in gross profit of $158,000 for the three months ended June 30, 2025, as compared to the prior period, was primarily due to an increase in revenue and overall product mix.

The increase in Europe revenue for the three months ended September 30, 2025 of $645,000 was the result of a general increase in demand for our products.

The increase in Asia revenue of $281,000 for the three months ended September 30, 2025 was primarily due to timing of orders. Revenues from our international distributors tend to fluctuate from period to period due to customer placement of larger but less frequent orders to benefit from quantity discounts and reduced shipping costs.

The increase in Latin America revenue for the three months ended September 30, 2025 of $67,000 was primarily due to timing of customer orders for overflow manufacturing.

The increase in Rest of World revenue for the three months ended September 30, 2025 of $258,000 was primarily due to timing of customer orders.

Cost of Revenue and Gross Profit

The cost of revenue and gross profit metrics for the three months ended September 30, 2025 and 2024 are as follows:

	Three Months Ended September 30,
(In thousands, except for percentages)	2025		2024		$ Change		% Change
Cost of Revenues	$	3,484	$	2,218	$	1,266		57%
Cost of Revenue as a % of Revenues		62%		62%
Gross Profit	$	2,120	$	1,361	$	759		56%
Gross Profit as a % of Revenues		38%		38%

The increase in gross profit of $759,000 for the three months ended September 30, 2025, as compared to the prior period, was primarily due to an increase in revenue and overall product mix.

Research and Development Expense

The research and development expense metrics for ~~the~~ the three months ended ~~June~~September 30, 2025 and 2024 are as follows:

	Three Months Ended June 30,
	Three Months Ended September 30,
(In thousands, except for percentages)	2025		2024		$ Change		% Change
Research and Development Expense	$	~~594~~575	$	~~470~~506	$	~~124~~69		2614%
Research and Development Expense as a % of Revenues		1510%		14%

Increases in research and development expenses ~~for~~ for the three months ended ~~June~~September 30, 2025 of $~~124~~69,000 were primarily due to increased product development to support new product releases.

Selling, General and Administrative Expense

The selling, general and administrative expense ~~metrics~~ metrics for the three months ended ~~June~~September 30, 2025 and 2024 are as follows:

	Three Months Ended June 30,
	Three Months Ended September 30,
(In thousands, except for percentages)	2025		2024		Change			% Change
Selling, General and Administrative Expense	$	1,~~965~~882	$	21,~~009~~705	$	~~(44~~177	)		(210%	)
Selling, General and Administrative Expense as a % of Revenues		4934%		5948%

The ~~decline~~increase in selling, general and administrative expenses for the three months ended ~~June~~September 30, 2025 of $44177,000 was the result of ongoing efforts to ~~contain~~generate ~~expenses~~increased ~~across~~revenues across all ~~parts~~geographic ~~of the company~~regions.

Other (Expense) Income, net

Other (expense) income, net for the three months ended September ~~June~~ 30, 2025 was $(~~147~~394,000) compared to $~~176~~387,000 for the three months ended ~~June~~September 30, 2024. Other (expense) income, net ~~in the current period~~ primarily ~~relates to exchange rate fluctuations, offset by the recognition of income of approximately $323,000 related to employee~~ ~~retention credits. Other (expense) income, net in the prior period primarily~~ relates to exchange rate fluctuations.

Income Tax Benefit (Expense)

Income tax benefit (expense) for the three months ended ~~June~~September 30, 2025 and 2024 was $1197,000 and ($~~146~~147,000), respectively. The benefit for the current period was related to an increase in in our Mexico deferred tax asset. The expense for the prior period is primarily related to the use of our Mexico deferred tax asset.

Net Loss

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

	Three Months Ended June 30,
	Three Months Ended September 30,
(In thousands, except per share data)	2025			2024
Net loss	$	(~~1,241~~534	)	$	(~~1,143~~610	)
Weighted-average shares outstanding: basic and diluted		1,~~641~~646			~~851~~1,034
Net loss per share: basic and diluted	$	(0.7632	)	$	(10.3459	)

2021

Comparison of the Six Months Ended September 30, 2025 and 2024

Revenue

The following table shows our consolidated total revenue and revenue by geographic region for the six months ended September 30, 2025 and 2024:

	Six Months Ended September 30,
(In thousands)	2025		2024		$ Change			% Change
United States	$	2,454	$	1,317	$	1,137			86%
Europe		3,619		2,794		825			30%
Asia		1,719		1,253		466			37%
Latin America		1,096		1,345		(249	)		(19%	)
Rest of the World		731		261		470			180%
Total	$	9,619	$	6,970	$	2,649			38%

The increase in United States revenue of $1,137,000 for the six months ended September 30, 2025 was primarily the result of an increase in revenue related to human health care products and over-the-counter animal health care products.

The increase in Europe revenue for the six months ended September 30, 2025 of $825,000 was the result of a general increase in demand for our products.

The increase in Asia revenue of $466,000 for the six months ended September 30, 2025 was primarily due to timing of orders. Revenues from our international distributors tend to fluctuate from period to period due to customer placement of larger but less frequent orders to benefit from quantity discounts and reduced shipping costs.

The decrease in Latin America revenue for the six months ended September 30, 2025 of $249,000 was primarily due to timing of customer orders for overflow manufacturing.

The increase in Rest of World revenue for the six months ended September 30, 2025 of $470,000 was primarily due to timing of customer orders.

Cost of Revenue and Gross Profit

The cost of revenue and gross profit metrics for the six months ended September 30, 2025 and 2024 are as follows:

	Six Months Ended September 30,
(In thousands, except for percentages)	2025		2024		$ Change		% Change
Cost of Revenues	$	6,035	$	4,303	$	1,732		40%
Cost of Revenue as a % of Revenues		63%		62%
Gross Profit	$	3,584	$	2,667	$	917		34%
Gross Profit as a % of Revenues		37%		38%

The increase in gross profit of $917,000 for the six months ended September 30, 2025, as compared to the prior period, was primarily due to an increase in revenue and overall product mix.

Research and Development Expense

The research and development expense metrics for the six months ended September 30, 2025 and 2024 are as follows:

	Six Months Ended September 30,
(In thousands, except for percentages)	2025		2024		$ Change		% Change
Research and Development Expense	$	1,169	$	976	$	193		20%
Research and Development Expense as a % of Revenues		12%		14%

Increases in research and development expenses for the six months ended September 30, 2025 of $193,000 were primarily due to increased product development to support new product releases.

Selling, General and Administrative Expense

The selling, general and administrative expense metrics for the six months ended September 30, 2025 and 2024 are as follows:

	Six Months Ended September 30,
(In thousands, except for percentages)	2025		2024		Change		% Change
Selling, General and Administrative Expense	$	3,847	$	3,714	$	133		4%
Selling, General and Administrative Expense as a % of Revenues		40%		53%

The increase in selling, general and administrative expenses for the six months ended September 30, 2025 of $133,000 was the result of ongoing efforts to generate increased revenues across all geographic regions.

Other (Expense) Income, net

Other (expense) income, net for the six months ended September 30, 2025 was $(541,000) compared to $563,000 for the six months ended September 30, 2024. Other (expense) income, net in the current period primarily relates to exchange rate fluctuations, offset by the recognition of income of approximately $323,000 related to employee retention credits. Other (expense) income, net in the prior period primarily relates to exchange rate fluctuations.

Income Tax Benefit (Expense)

Income tax benefit (expense) for the six months ended September 30, 2025 and 2024 was $198,000 and ($293,000), respectively. The benefit for the current period was related to an increase in our Mexico deferred tax asset. The expense for the prior period is primarily related to the use of our Mexico deferred tax asset.

Net Loss

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

	Six Months Ended September 30,
(In thousands, except per share data)	2025			2024
Net loss	$	(1,775	)	$	(1,753	)

Weighted-average shares outstanding: basic and diluted		1,643			943

Net loss per share: basic and diluted	$	(1.08	)	$	(1.86	)

Liquidity and Capital Resources

We reported a net loss of $1,~~241~~775,000 and $1,~~143~~753,000 for the ~~three~~six months ended ~~June~~September 30, 2025 and ~~June~~September 30, 2024, respectively. At ~~June~~September 30, 2025 and March 31, 2025, our accumulated ~~deficit~~ deficit amounted to $199,~~047~~581,000 and $197,806,000, respectively. At ~~June~~September 30, 2025 and March 31, 2025, we had cash and cash equivalents of $3,~~605~~035,000 and $5,374,000, respectively. At ~~June~~September 30, 2025 and March 31, 2025, we had working capital of $8,~~259~~179,000 and $8,552,000, respectively.

We believe we have access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, we cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the economic climate in the U.S. deteriorates, our ability to raise additional capital could be negatively impacted. If we are unable to secure additional capital, we may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet our obligations. These measures could cause significant delays our continued efforts to commercialize products, which is critical to the realization of our business plan and our future operations. This uncertainty along with the our history of losses indicates that there is substantial doubt about the our ability to continue as a going concern within one year after the date that these financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should we be unable to continue as a going concern.

Sources of Liquidity

Since our inception, substantially all of our operations have been financed through sales of equity securities. Other sources of financing that we have used to date include our revenues, as well as various loans and the sale of certain assets to customers.

Since ~~July~~October 1, 2024, substantially all of our operations have been financed through cash on hand and the following transactions:

	·	Proceeds of $2958,~~238,~~000, net of offering expenses, from the sale of common stock at various dates; and
	·	Proceeds of $619,000 related to employee retention credits for the years 2020 and 2021.

Cash Flows

The following table presents a summary of our ~~condensed~~ condensed consolidated cash flows for operating, investing and financing activities for the three months ended ~~June~~September 30, 2025 and 2024 as well as balances of cash and cash equivalents and working capital:

	Three Months ended June 30,
	Six Months ended September 30,
(In thousands)	2025			2024
Net cash provided by (used in):
Operating activities	$	(2,~~015~~650	)	$	(~~912~~558	)
Investing activities		(~~106~~116	)		(531	)
Financing activities		(58120	)		~~636~~2,080
Effect of exchange rates on cash		~~410~~547			(~~258~~541	)
Net change in cash and cash equivalents		(12,~~769~~339	)		~~(539~~950	)
Cash and cash equivalents, beginning of the period		5,374			3,128
Cash and cash equivalents, end of the period	$	3,~~605~~035		$	24,~~589~~078
Working capital (1), end of period	$	8,~~259~~179		$	8,~~176~~912

⁽¹⁾

Defined as current assets minus current liabilities.

Net cash used in operating activities during the three months ended June 30, 2025 was $2,015,000, primarily due to our net loss of $1,241,000, an increase in accounts receivable of $216,000, an increase in inventory of $652,000, an increase in prepaid expenses of $819,000 offset by stock compensation of $57,000, and an increase in accounts payable of $1,026,000.24

Net cash used in operating activities during the ~~three~~ three months ended ~~June~~September 30, ~~2024~~2025 was $~~912~~2,650,000, primarily due to aour net loss of $1,~~143~~775,000, an increase in accounts receivable of $294,000, an increase in inventory of $444,000, an increase in prepaid expenses of $834,000 offset by stock ~~related~~ compensation ~~expense~~of $96,000, and an increase in accounts payable of $~~107~~360,000.

Net cash used in ~~investing~~operating activities ~~was~~during ~~$106,000 for~~ the ~~three~~ six months ended ~~June~~September 30, ~~2025~~2024 was $558,000, primarily ~~related~~due to ~~the~~a ~~purchase~~net loss of ~~equipment~~$1,753,000 offset by decrease in prepaid expenses of $1,134,000.

Net cash used in investing activities was $5116,000 for the three months ended ~~June~~September 30, ~~2024~~2025, primarily related to the purchase of equipment.

Net cash used in ~~financing~~investing activities was $5831,000 for ~~the~~six ~~three~~ months ended ~~June~~September 30, ~~2025~~2024, primarily related to ~~exercise~~the ofpurchase ~~stock options~~ of ~~$23,000 offset by $81,000 of principal payments on a short-term loan related to financing of insurance premiums~~equipment.

Net cash ~~provided~~used byin financing activities was $~~636~~120,000 for the three months ended ~~June~~September 30, ~~2024~~2025, primarily ~~due~~related to ~~the~~exercise ~~sale~~ of ~~common~~ stock options of $~~748~~44,000 offset by $~~119~~164,000 of principal payments on a short-term loan related to financing of insurance premiums.

21Net cash provided by financing activities was $2,080,000 for the six months ended September 30, 2024, primarily due to net proceeds from the sale of common stock of $2,289,000 offset by $241,000 of principal payments on a short-term loan related to financing of insurance premiums.

Material Trends and Uncertainties

We rely on certain key customers for a significant portion of our revenues. In the future, a small number of customers may continue to represent a significant portion of our total revenues in any given period. These customers may not consistently purchase our products at a particular rate over any subsequent period.

We are exposed to risk from foreign currency devaluation for both the Mexico Peso and the Euro versus the US dollar. Risk related to foreign currency valuation tends to be unpredictable and can be affected by various factors outside of our control.

We face a substantial Mexico tax liability, intercompany debt, unpaid technical assistance charges and accrued interest. These amounts are due in 2027. At this time, management believes there are sufficient assets on the balance sheet to cover any tax obligation without interrupting our operations or business. We have engaged tax professionals to review all options to limit our exposure to these amounts and to proceed in a manner that is most advantageous to us.

We also closely monitor global economic conditions, including the risk of economic downturn or recession, the prospect of new or increased tariffs, as well as overall consumer sentiment, any of which may impact our financial results.

On July 4, 2025, the United States enacted tax ~~reform~~ reform legislation through the One Big Beautiful Bill Act ("OBBBA"), which changes existing U.S. tax laws, including extending or making permanent certain provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. WeThe ~~anticipate~~Company anticipates an insignificant impact to deferred tax assets and liabilities and to income taxes payable in the period of enactment. We continue to evaluate the impact the new legislation will have on our consolidated financial statements.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance relating to our deferred tax assets. Periodically, we evaluate and adjust estimates accordingly.

Off-Balance Sheet Transactions

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our ~~Chief~~ Chief Executive Officer and Chief Financial Officer, has evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) ~~under~~ under the Securities Exchange Act of 1934, as amended) prior to the filing of this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were, in design and operation effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls ~~over~~ over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the second ~~first~~ quarter of fiscal year 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.

2326

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

On occasion, we may be involved in legal matters arising in the ordinary course of our business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of comprehensive loss.

Item 1A.

Risk Factors

There have been no material changes from risk factors previously disclosed in our annual report on Form 10-K for the fiscal year ended March 31, 2025, as filed with the SEC June 17, 2025.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

We did not issue any unregistered securities during the quarter ended ~~June~~September 30, 2025 and through ~~August~~November 74, 2025.

Item 3.

Default Upon Senior Securities

We did not default upon any senior securities ~~during~~ during the quarter ended ~~June~~September 30, 2025.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

During the quarter ended ~~June~~September 30, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

Item 6.

Exhibits

Exhibit Index

Exhibit No.	Description
3.1	Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective January 30, 2006 (included as exhibit 3.1 of the Company’s Annual Report on Form 10-K filed June 20, 2007, and incorporated herein by reference).
3.2	Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective October 22, 2008 (included as exhibit A in the Company’s Definitive Proxy Statement on Schedule 14A filed July 21, 2008, and incorporated herein by reference).
3.4	Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective March 29, 2013 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed March 22, 2013, and incorporated herein by reference).
3.5	Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective December 4, 2014 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 8, 2014, and incorporated herein by reference).
3.6	Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective October 22, 2015 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed October 27, 2015, and incorporated herein by reference).
3.7	Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective June 24, 2016 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 28, 2016, and incorporated herein by reference).
3.8	Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective December 6, 2016 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).
3.9	Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective December 6, 2016 (included as exhibit 3.2 to the Company’s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).
3.10	Amendment No. 1 to Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective June 14, 2024 (included as exhibit 3.10 to the Company’s Annual Report on Form 10-K filed June 17, 2024, and incorporated herein by reference).
3.11	Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock, filed with the Delaware Secretary of State on April 24, 2012 (included as exhibit 4.2 to the Company’s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).
3.12	Certificate of Designation of Series B Preferred Stock, effective October 18, 2016 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by references).
3.13	Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective June 19, 2019 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 19, 2019, and incorporated herein by reference).
3.14	Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective August 29, 2024 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed August 28, 2024, and incorporated herein by reference).
4.1	Specimen Common Stock Certificate (included as exhibit 4.1 to the Company’s Annual Report on Form 10-K filed June 28, 2017, and incorporated herein by reference).
4.2	Section 382 Rights Agreement, dated as of October 18, 2016, between Oculus Innovative Sciences, Inc. and Computershare Inc., which includes the Form of Certificate of Designation of Series B Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C (included as exhibit 4.1 to the Company’s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by reference).
10.1	Form of Indemnification Agreement between Oculus Innovative Sciences, Inc. and its officers and directors (included as exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.2	Office Lease Agreement, dated May 18, 2006, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish) (included as exhibit 10.10 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).

2428

3.8	Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective December 6, 2016 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).
3.9	Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective December 6, 2016 (included as exhibit 3.2 to the Company’s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).
3.10	Amendment No. 1 to Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective June 14, 2024 (included as exhibit 3.10 to the Company’s Annual Report on Form 10-K filed June 17, 2024, and incorporated herein by reference).
3.11	Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock, filed with the Delaware Secretary of State on April 24, 2012 (included as exhibit 4.2 to the Company’s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).
3.12	Certificate of Designation of Series B Preferred Stock, effective October 18, 2016 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by references).
3.13	Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective June 19, 2019 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 19, 2019, and incorporated herein by reference).
3.14	Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective August 29, 2024 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed August 28, 2024, and incorporated herein by reference).
4.1	Specimen Common Stock Certificate (included as exhibit 4.1 to the Company’s Annual Report on Form 10-K filed June 28, 2017, and incorporated herein by reference).
4.2	Section 382 Rights Agreement, dated as of October 18, 2016, between Oculus Innovative Sciences, Inc. and Computershare Inc., which includes the Form of Certificate of Designation of Series B Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C (included as exhibit 4.1 to the Company’s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by reference).
10.1	Form of Indemnification Agreement between Oculus Innovative Sciences, Inc. and its officers and directors (included as exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.2	Office Lease Agreement, dated May 18, 2006, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish) (included as exhibit 10.10 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.3	Office Lease Agreement, dated July 2003, between Oculus Innovative Sciences, B.V. and Artikona Holding B.V. (translated from Dutch) (included as exhibit 10.11 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.4	Form of Director Agreement (included as exhibit 10.20 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.5	Amendment to Office Lease Agreement, effective February 15, 2008, by and between Oculus Innovative Sciences Netherlands B.V. and Artikona Holding B.V. (translated from Dutch) (included as exhibit 10.4432 to the Company’s Annual Report on Form 10-K filed June 13, 2008, and incorporated herein by reference).
10.6†	Exclusive Sales and Distribution Agreement, dated November 6, 2015, by and between Oculus Innovative Sciences, Inc. and Manna Pro Products, LLC (included as exhibit 10.1 to the Company’s 8-K filed March 23, 2016 and incorporated herein by reference).
10.7†	Asset Purchase Agreement dated October 27, 2016, between Oculus Innovative Sciences, Inc. and Invekra, S.A.P.I de C.V. (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).
10.8†	Amendment Agreement to Acquisition Option dated October 27, 2016, by and between More Pharma Corporation S. de R.L. de C.V. and Oculus Technologies of Mexico, S.A. de C.V. (included as exhibit 10.2 to the Company’s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).
10.9	2016 Equity Incentive Plan (included as exhibit A to the Company’s Definitive Proxy Statement on Schedule 14A filed July 29, 2016, and incorporated herein by reference).
10.10⸸+	Asset Purchase Agreement dated May 14, 2019, between Sonoma Pharmaceuticals, Inc. and Petagon, Ltd. (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 22, 2019, and incorporated herein by reference).
10.11⸸+	Asset Purchase Agreement dated February 21, 2020, between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, DMCC (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 27, 2020, and incorporated herein by reference.)
10.12⸸+	License, Distribution and Supply Agreement by and between Sonoma Pharmaceuticals, Inc. and Brill International, S.L. dated May 19, 2020 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 26, 2020, and incorporated herein by reference.)
10.13⸸	Licensing Agreement between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, effective July 27, 2020 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 6, 2020, and incorporated herein by reference).
10.14	2021 Equity Incentive Plan (included as appendix on the Company’s Definitive Proxy Statement on Schedule 14A filed July 29, 2021 and incorporated herein by reference).
10.15	2024 Equity Incentive Plan (included as appendix on the Company’s Definitive Proxy Statement on Schedule 14A filed July 1, 2024 and incorporated herein by reference).
10.16+⸸	Exclusive License and Distribution Agreement between the Company and Dyamed Biotech Pte Ltd., dated November 4, 2021 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 9, 2021, and incorporated herein by reference).
10.17+⸸	Exclusive License and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Anlicare International dated January 18, 2022 (included as exhibit 10.2 to the Company’s Current Report on Form 8-K filed January 20, 2022, and incorporated herein by reference).
10.18	Sonoma Pharmaceuticals, Inc. Non-Employee Director Compensation Program and Stock Ownership Guidelines, revised by the Board of Directors on December 29, 2022 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed December 30, 2022, and incorporated herein by reference).
10.19	Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated June 16, 2023 (included as exhibit 10.38 to the Company’s Annual Report on Form 10-K filed June 21, 2023, and incorporated herein by reference).
10.20	Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated June 16, 2023 (included as exhibit 10.39 to the Company’s Annual Report on Form 10-K filed June 21, 2023, and incorporated herein by reference).
10.21	First Amendment to the Lease between the Company and Westland Development Services, Inc., dated June 21, 2023 (included as exhibit 10.38 to the Company’s Quarterly Report on Form 10-Q filed November 13, 2023, and incorporated herein by reference).
10.22	At Market Issuance Sales Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc., dated September 26, 2025 (included as exhibit 1.1 to the Company’s Current Report on Form 8-K filed September 26, 2025, and incorporated herein by reference).

2529

10.13⸸	Licensing Agreement between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, effective July 27, 2020 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 6, 2020, and incorporated herein by reference).
10.14	2021 Equity Incentive Plan (included as appendix on the Company’s Definitive Proxy Statement on Schedule 14A filed July 29, 2021 and incorporated herein by reference).
10.15	2024 Equity Incentive Plan (included as appendix on the Company’s Definitive Proxy Statement on Schedule 14A filed July 1, 2024 and incorporated herein by reference).
10.16+⸸	Exclusive License and Distribution Agreement between the Company and Dyamed Biotech Pte Ltd., dated November 4, 2021 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 9, 2021, and incorporated herein by reference).
10.17+⸸	Exclusive License and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Anlicare International dated January 18, 2022 (included as exhibit 10.2 to the Company’s Current Report on Form 8-K filed January 20, 2022, and incorporated herein by reference).
10.18	Sonoma Pharmaceuticals, Inc. Non-Employee Director Compensation Program and Stock Ownership Guidelines, revised by the Board of Directors on December 29, 2022 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed December 30, 2022, and incorporated herein by reference).
10.19	Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated June 16, 2023 (included as exhibit 10.38 to the Company’s Annual Report on Form 10-K filed June 21, 2023, and incorporated herein by reference).
10.20	Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated June 16, 2023 (included as exhibit 10.39 to the Company’s Annual Report on Form 10-K filed June 21, 2023, and incorporated herein by reference).
10.21	First Amendment to the Lease between the Company and Westland Development Services, Inc., dated June 21, 2023 (included as exhibit 10.38 to the Company’s Quarterly Report on Form 10-Q filed November 13, 2023, and incorporated herein by reference).
10.22	Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC, dated December 15, 2023 (included as exhibit 1.1 to the Company’s Current Report on Form 8-K filed December 15, 2023, and incorporated herein by reference).
10.23	Offer letter to Jerome Dvonch dated February 7, 2024 (included as exhibit 10.41 to the Company’s Quarterly Report on Form 10-Q filed February 8, 2024, and incorporated herein by reference).
10.24	Offer letter to John Dal Poggetto dated February 7, 2024 (included as exhibit 10.42 to the Company’s Quarterly Report on Form 10-Q filed February 8, 2024 and incorporated herein by reference).
10.25	Amendment No. 1 to Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC., dated March 8, 2024 (included as exhibit 1.1 to the Company’s Current Report on Form 8-K filed March 8, 2024, and incorporated herein by reference).
10.26⸸+	Distribution Agreement, dated August 19, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 21, 2024, and incorporated herein by reference).
10.27+	Amendment No. 1 to Distribution Agreement, dated October 17, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 22, 2024, and incorporated herein by reference).
10.28⸸+	Master Supply Agreement, dated January 29, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 30, 2025, and incorporated herein by reference).
10.29⸸+	Amendment No. 1 to Master Supply Agreement, dated March 21, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 25, 2025, and incorporated herein by reference).
10.30⸸+	Amendment No. 2 to Master Supply Agreement, dated June 2, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation (included as exhibit 10.30 to the Company’s Annual Report on Form 10-K filed June 17, 2025, and incorporated herein by reference).
10.31⸸+*	Amendment No. 3 to Master Supply Agreement, dated July 23, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation.
10.31⸸+	Amendment No. 3 to Master Supply Agreement, dated July 23, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation (included as exhibit 10.31 to the Company’s Quarterly Report on Form 10-Q filed August 7, 2025, and incorporated herein by reference)
10.32⸸+	Distribution and Supply Agreement, effective March 28, 2025, by and between Sonoma Pharmaceuticals, Inc. and Phase One Health, LLC (included as exhibit 10.31 to the Company’s Annual Report on Form 10-K filed June 17, 2025, and incorporated herein by reference).
10.33	Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated October 3, 2025 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 9, 2025, and incorporated herein by reference).
21.1	List of Subsidiaries (included as exhibit 21.1 to the Company’s Annual Report on Form 10-K filed June 28, 2017, and incorporated herein by reference).
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).

31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).

*	Filed herewith.
†	Confidential treatment has been granted with respect to certain portions of this agreement.
⸸	Certain portions of the exhibit have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.
+	The schedules to the exhibit have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of any such schedules to the SEC upon request.

Copies of above exhibits not contained herein are available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Sonoma Pharmaceuticals, Inc., 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301.

2730

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 7, 2025	By:	/s/ Amy Trombly
Date: November 4, 2025	By:	/s/ Amy Trombly
		Amy Trombly President and Chief Executive Officer, (Principal Executive Officer)
Date: August 7, 2025	By:	/s/ Jerome Dvonch
Date: November 4, 2025	By:	/s/ Jerome Dvonch
		Jerome Dvonch
		Chief Financial Officer
		(Principal Financial and Principal Accounting Officer)

2831

Filing Compare · Sonoma Pharmaceuticals, Inc.